AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Study Overview: AstraZeneca, in collaboration with Daiichi Sankyo, is conducting a Phase III, randomised, open-label study titled ‘TROPION-Lung12’. The study aims to evaluate the efficacy and safety of adjuvant Datopotamab Deruxtecan (Dato-DXd) in combination with Rilvegostomig or Rilvegostomig alone versus the standard of care (SoC) in patients with Stage I adenocarcinoma non-small cell lung cancer (NSCLC) who are ctDNA-positive or have high-risk pathological features. This research is significant as it targets early-stage lung cancer patients who have undergone complete tumor resection, potentially improving post-surgical outcomes.
Intervention/Treatment: The study tests two main interventions: Dato-DXd combined with Rilvegostomig, and Rilvegostomig monotherapy. Both are administered as intravenous infusions every three weeks. The purpose is to assess their effectiveness against the standard care options, which include observation or chemotherapy.
Study Design: This interventional study employs a randomized, parallel assignment model with a 2:1:2 allocation ratio. Participants are divided into three groups: Dato-DXd with Rilvegostomig, Rilvegostomig alone, and SoC. The study is open-label but sponsor-blinded, with outcomes assessors masked to treatment allocation. The primary goal is treatment efficacy.
Study Timeline: The study began on October 15, 2024, with its most recent update submitted on July 9, 2025. These dates are crucial for investors to track the study’s progress and anticipate potential results.
Market Implications: This study could significantly impact AstraZeneca’s stock performance, especially if the results demonstrate superior efficacy of Dato-DXd and Rilvegostomig over current treatments. Positive outcomes could enhance investor sentiment and position AstraZeneca competitively within the oncology market, particularly against other pharmaceutical companies focusing on lung cancer therapies.
The study is currently recruiting, with ongoing updates available on the ClinicalTrials portal.